MKI67 and breast carcinoma: In breast cancer, patients with high Ki67 expression (> 30%) had worse disease-free survival and overall survival after adjuvant tamoxifen therapy (Elzawahry et al. 2013), while they could benefit from chemotherapy (Criscitiello et al. 2014).